February 17, 2017 08:52 AM EST
Pharma

Gilead of­floads a PhII-ready ad­dic­tion ther­a­py to an up­start which knows this drug well

Arsalan Arif

Founder

Eight years ago, Gilead snapped up CV Ther­a­peu­tics and its angi­na drug Ranexa for $1.4 bil­lion, look­ing to beef up its port­fo­lio of car­dio drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Ex­clu­sive: British start­up rais­es $16M to find genes that rewind the epi­ge­net­ic clock

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times